Huapai Biotechnology (Group) Co., Ltd. is a group enterprise dedicated to the research, development, production, sales, and technical services of animal health products, including high-end veterinary biological vaccines, antibodies, diagnostic reagents, traditional Chinese veterinary medicines, and chemical pharmaceuticals. Recognized as a "National Enterprise Technology Center" and "National High-tech Enterprise," the Group operates a National-Local Joint Engineering Laboratory for Veterinary Nucleic Acid and Subunit Vaccine Preparation Technology, an academician (expert) innovation workstation, and a CNAS-certified Quality Evaluation Center for Veterinary Biologics. Headquartered at No. 6 Mengzi Road, Shipan Street, Chengdu Eastern New Area, China, the company has a total investment exceeding CNY 1.5 billion.

The Group owns five veterinary biologics production bases:

-Huapai Group Headquarters

-Chongqing Auleon Biologicals

-Chongqing Health Forever Biotechnology

-Tengchong Huayu Biology

-Gaoling Biology

Additionally, it operates Jinghua Pharmaceutical, an animal health pharmaceutical production base.

R&D Capabilities

-With 16 Ph.D. holders, 66 master’s degree holders, and over 70% of employees holding bachelor’s degrees or higher, the Group has secured:

-50 veterinary biologics approvals

-1 National Science and Technology Progress Award (Second Prize)

-2 Shennong China Agricultural Science and Technology Achievement Awards (First Prize)

-31 new veterinary drug certificates

-24 national invention patents

-73 utility model patents

-Over 40 products in development

Innovative Milestones

-Huapai Group · Huayu Biology: Operates China’s first foot-and-mouth disease virus-like particle (VLPs) vaccine production line, equipped with a dedicated Biosafety Level 3 (BSL-3) laboratory for veterinary vaccines.

-Huapai Group · Auleon Biologicals: The sole global manufacturer of genetically engineered subunit vaccines for sheep echinococcosis (hydatid disease), and the exclusive global supplier of hydatidosis vaccines.

-Huapai Group · Huapai Biology: Pioneered the world’s first poultry DNA vaccine production line, specializing in "H5+H7" avian influenza DNA vaccines for advanced poultry disease control.

 Adhering strictly to the WHO's Good Manufacturing Practices (GMP) for veterinary drugs, the Group ensures a batch-to-batch variation rate of less than 1.5% (v/v) through a fully integrated digital quality traceability system and international ISO certifications. Its proprietary freeze-dried protectant technology and antigen purification processes enhance vaccine potency by over 30%. The products have served 14 of the top 20 global breeding groups, including Charoen Pokphand Group and Muyuan Foods, and are exported to 22 countries across Southeast Asia, the Middle East, and Africa.

Huapai Group has officially joined the Food and Agriculture Organization (FAO) of the United Nations, committed to serving the global livestock industry.

Guided by the philosophy "Quality as the Foundation, Innovation as the Core," the Group allocates 12% of its annual revenue to R&D, with seven active innovation projects such as DNA vaccines, genetic engineering subunit vaccines, and virus-like particle (VLPs) vaccines. We invite global partners to collaborate in building an animal health ecosystem that safeguards food safety, prevents zoonotic diseases through advanced biotechnology, and contributes Chinese expertise to advancing a shared future for humanity.